Cliantha Research is a leading service provider for Biosimilar s clinical development Our diverse and expert team brings with it hands on experience in development including Regulatory support Medical Affairs and execution of Phase I IV studies across multiple geographies Cliantha Research is recognized among the Top 5 CROs for the conduct of Biosimilar Clinical Trials Globally by Global Data Report April 2017 Dr Chirag Shah Director Late Phase Trials will speak on Regulatory considerations in Clinical Study Design of Biosimilars at 12th Biosimilars Congregation 2018 in London UK on 27th 28th February 2018 If you wish to set up a meeting with Dr Chirag Shah during the event contact us at cshah cliantha in

#Biosimilars
Cliantha Research is a leading service provider for Biosimilar's clinical development. Our diverse and expert team brings with it, hands-on experience in #Biosimilars development including Regulatory support, Medical Affairs and execution of Phase I-IV studies across multiple geographies. Cliantha Research is recognized among the “Top 5 CROs for the conduct of Biosimilar Clinical Trials Globally

Cliantha Research is a leading service provider for Biosimilar's clinical development. Our diverse and expert team brings with it, hands-on experience in #Biosimilars development including Regulatory support, Medical Affairs and execution of Phase I-IV studies across multiple geographies. Cliantha Research is recognized among the “Top 5 CROs for the conduct of Biosimilar Clinical Trials Globally" by Global Data Report, April 2017.

Dr. Chirag Shah, Director - Late Phase Trials will speak on "Regulatory considerations in Clinical Study Design of Biosimilars" at 12th Biosimilars Congregation 2018 in London, UK, on 27th & 28th February 2018. If you wish to set up a meeting with Dr. Chirag Shah, during the event contact us at cshah@cliantha.in.

Cliantha Research is a leading service provider for Biosimilar's clinical development. Our diverse and expert team brings with it, hands-on experience in #Biosimilars development including Regulatory support, Medical Affairs and execution of Phase I-IV studies across multiple geographies. Cliantha Research is recognized among the “Top 5 CROs for the conduct of Biosimilar Clinical Trials Globally" by Global Data Report, April 2017. Dr. Chirag Shah, Director - Late Phase Trials will speak on "Regulatory considerations in Clinical Study Design of Biosimilars" at 12th Biosimilars Congregation 2018 in London, UK, on 27th & 28th February 2018. If you wish to set up a meeting with Dr. Chirag Shah, during the event contact us at cshah@cliantha.in.

Let's Connect

sm2p0